REPOSITIONING INTELLIGENCE — EVIDENCE REPORT
============================================
Generated: Nov 12, 2026, 11:53 PM UTC

DISCLAIMER: This report is for research and informational use only.
It is NOT medical advice, diagnosis, or treatment guidance.

DRUG–DISEASE PAIRING
--------------------
Drug:     Dexamethasone
Disease:  COVID-19
Target:   Glucocorticoid receptor

EVIDENCE GRADE: Strong Repurposing Signal
Confidence Score: 91%
Evidence Level: Level 1 (large RCT)
Trial Phase: Phase III (platform trial)

MECHANISM
---------
Glucocorticoid-mediated suppression of cytokine storm in severe COVID-19.

OUTCOMES
--------
28-day mortality reduction in patients requiring oxygen; no benefit in mild disease.

AI SUMMARY (generated March 15, 2026)
-----------
The RECOVERY trial provided definitive evidence for dexamethasone 6 mg daily in hospitalized COVID-19 patients on supplemental oxygen or ventilation. WHO and NIH guidelines endorse this indication.

KNOWN RISKS
-----------
• Hyperglycemia
• Immunosuppression and infection risk
• Adrenal suppression with prolonged use
• Mood changes and insomnia

CITATIONS
---------
[PUBMED] 32678530: Dexamethasone in hospitalized patients with Covid-19 (RECOVERY)
  https://pubmed.ncbi.nlm.nih.gov/32678530/

[CLINICALTRIALS] NCT04381936: RECOVERY trial
  https://clinicaltrials.gov/study/NCT04381936

PUBMED IDs: 32678530
CLINICAL TRIAL IDs: NCT04381936

LAST VERIFIED: June 22, 2026
LAST UPDATED:  June 22, 2026
REVIEW STAGE:  published

---
Repositioning Intelligence Platform · Research Mode